On ECHEMI
Home > Drugs > Warfarin Sodium Tablets

Warfarin Sodium Tablets

Function and Efficacy

This product is a medium-acting anticoagulant of the dicoumarin class. Its mechanism of action is to competitively counteract the effect of vitamin K, inhibit the synthesis of coagulation factors in hepatocytes, and also has the effect of reducing thrombin-induced platelet aggregation reaction, thus having anticoagulant and antiplatelet aggregation functions.

Ingredients

Chemical name: 3-(3-oxo-1-phenylbutyl)-4-hydroxy-2H-1-benzopyrandione sodium salt and isopropanol inclusion. Molecular formula: C19H15NaO4 Molecular weight: 330.31

Name Description Content CAS NO. Manufacturer
Warfarin sodiumIngredients

This product is a medium-acting anticoagulant of the dicoumarin class. Its mechanism of action is to competitively counteract the effect of vitamin K, inhibit the synthesis of coagulation factors in hepatocytes, and also has the effect of reducing thrombin-induced platelet aggregation reaction, thus having anticoagulant and antiplatelet aggregation functions.

More
129-06-6 22

Appearance

This product is a sugar-coated tablet, which appears white after removing the sugar coating.

Indication

Suitable for patients who need long-term continuous anticoagulation: ① It can prevent the formation and development of blood clots and is used to treat thromboembolic diseases; ② It can treat venous thrombosis after surgery or trauma, and can be used as an auxiliary medication for myocardial infarction; ③ It can be used as a preventive medication for patients who have had thromboembolic diseases and those who are at risk of postoperative thrombotic complications.

Usage and Dosage

Oral administration, common dosage for adults: avoid shock treatment, take 3-4 mg orally on the first to third days (half the dose is sufficient for the elderly, the weak and diabetic patients), and after 3 days, give a maintenance dose of 2.5-5 mg per day (the dose can be adjusted with reference to the coagulation time so that the INR value reaches 2-3). Because this product takes effect slowly, a short-term hypercoagulable state may exist in the first three days of treatment due to the inhibition of plasma anticoagulant protein cells. If an anticoagulant effect is required immediately, heparin can be used at the same time at the beginning, and heparin can be discontinued after this product fully exerts its anticoagulant effect. A small amount of warfarin can be secreted by breast milk. Lactating women take 5-10 mg per day, and the blood drug concentration is generally 0.48-1.8 μg/ml. The drug concentration in breast milk and infant plasma is extremely low, and has little effect on infants.

Adverse Reactions

Overdose can easily cause various bleeding. Early manifestations include ecchymosis, purpura, gingival bleeding, epistaxis, prolonged wound bleeding, and excessive menstrual flow. Bleeding can occur in any part, especially the urinary and digestive tracts. Intestinal wall hematoma can cause subacute intestinal obstruction, and subdural intracranial hematoma and puncture site hematoma can also be seen. Occasional adverse reactions include nausea, vomiting, diarrhea, itchy rash, allergic reactions and skin necrosis. Large amounts of oral administration may even cause bilateral breast necrosis, microangiopathy or hemolytic anemia, and extensive skin gangrene; excessive doses at one time are especially dangerous.

Precautions

It is contraindicated in patients with liver and kidney damage, severe hypertension, coagulation disorder with bleeding tendency, active ulcer, trauma, threatened abortion, and recent surgery. It is contraindicated during pregnancy. It should be used with caution in the elderly or during menstruation.

Special Population Medication

Precautions for children: The dosage should be adjusted according to individual needs. Precautions for pregnancy and lactation: It is forbidden to use in patients with threatened abortion and during pregnancy, and should be used with caution during menstruation. Precautions for the elderly: Use with caution in the elderly.

Drug Interactions

Drugs that enhance the anticoagulant effect of this product include: aspirin, sodium salicylate, glucagon, quinidine, indomethacin, phenylbutazone, quinine, uric acid, tolbutamide, metronidazole, allopurinol, erythromycin, chloramphenicol, certain aminoglycoside antibiotics, cephalosporins, beniodarone, cimetidine, clofibrate, dextrothyroxine, acetaminophen, etc. Drugs that reduce the anticoagulant effect of this product include: phenytoin sodium, barbiturates, oral contraceptives, estrogen, cholestyramine, rifampicin, vitamin K, chlorthalidone, spironolactone, primidone, corticosteroids, etc. Drugs that cannot be used in combination with this product include: epinephrine hydrochloride, amikacin, vitamin B12, metaraminolamine, oxytocin, chlorpromazine hydrochloride, vancomycin hydrochloride, etc. When this product is used in combination with chloral hydrate, its efficacy and toxicity are enhanced, so it should be used with caution in a reduced dose. Impaired absorption or decreased synthesis of vitamin K also affects the anticoagulant effect of this product.

Storage

Keep away from light and store in sealed container.

Packaging Specification

5mg

Validity Period

24 months.

Manufacturer

Beijing Jialin Pharmaceutical Co., Ltd.

  • Founded in:

    1977-08-05
  • Address:

    No. 2 Jiuxianqiao Road, Dashanzi, Dongzhimenwai, Chaoyang District, Beijing
  • Tax NO.:

    911101051016610948
  • Registered Funds:

    30.5 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.